TABLE 4.

Sensitivity and subgroup palsy and pediatric mortality analyses of metaanalysis on effect of magnesium sulfate on cerebral

Subgroup		No of trials	Relative risk (95% Cl)	I2 (%)
CEREBRAL PALSY
Statistical model
	Fixed effects	630–33,35	0.69 (0.55–0.88)	4.4
	Random effects	630–33, 35	0.70 (0.54–0.90)	NA
Modified Jadad quality score
	>4	4 31–33,35	0.69 (0.54–0.88)	0.0
	≤4	230a,b	0.95(0.02–44.91)	71.1
Completeness of follow-up of randomized fetuses
	≥95%	331,34,35	0.69 (0.54–088)	0.0
	<95% or unreported	330,32	0.83 (0.28–2.43)	43.5
Aim of the treatment
	Neuroprotective	430a,31,33,35	0.71 (0.55–0.91)	25.2
	Other aims	230b, 32	0.37(0.09–1.58)	0.0
Median total dose of magnesium sulfate
	≤4 grams	230a, 33	1.37(0.18–10.70)	56.5
	>4 grams	430b,31,32,35	0.67(0.51–0.88)	0.0
Gestational age at trial entry
	<34 weeks	630–33,35	0.69 (0.55–0.88)	4.4
	<32 weeks	331,32,35	0.69(0.52–0.91)	0.0
	<30 weeks	231;32	0.86(0.56–1.31)	0.0
PEDIATRIC MORTALITY
Statistical model
	Fixed effects	629,31–33,35	1.01 (0.89–1.14)	38.9
	Random effects	629,31–33,35	0.99(0.82–1.19)	NA
Modified Jadad quality score
	>4	431–33,35	0.99(0.87–1.11)	27.9
	≤<4	229a,b	6.61 (1.21–36.11)	31.0
Completeness of follow-up of randomized fetuses
	≥95%	331,34,35	0.94(0.79–1.12)	40.7
	<95%	329,32	1.10(0.93–1.30)	49.5
Aim of the treatment
	Neuroprotective	429a,31,33,35	0.95(0.80–1.12)	19.6
	Other aims	229b,32	2.83(0.21–38.80)	72.9
Median total dose of magnesium sulfate
	≤4 grams	229a,33	0.88(0.57–1.35)	0.0
	>4 grams	429b,31,32,35	1.01 (0.80–1.28)	59.3
Gestational age at trial entry
	<34 weeks	629,31–33,35	1.01 (0.89–1.14)	38.9
	<32 weeks	331;32;35	1.03(0.83–1.28)	65.5
	<30 weeks	231,32	0.97(0.67–1.41)	83.0

Cl, confidence interval; NA, not applicable

^aNeuroprotective arm of study by Mittendorf et al.^{29, 30}

^bTocolytic arm of study by Mittendorf et al.^29,30